Completed PHASE2 INTERVENTIONAL 2-arm NCT03544814

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

EGFR Tyrosine Kinase Inhibitor Combined With Concurrent or Sequential Chemotherapy for Advanced Lung Cancer Patients of Gradual Progression After First-line EGFR-TKI Therapy: a Randomized Controlled Study

Sponsor: Shanghai Chest Hospital

Conditions EGFR Activating Mutation Lung Adenocarcinoma

Interventions first icotinib and then pemetrexed plus cisplatin icotinib combined with pemetrexed plus cisplatin

Updated 5 times since 2018 Last updated: Oct 11, 2019 Started: Jan 1, 2015 Primary completion: Jun 1, 2017 Completion: Dec 30, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03544814, this PHASE2 trial focuses on EGFR Activating Mutation and Lung Adenocarcinoma and remains completed. Sponsored by Shanghai Chest Hospital, it has been updated 5 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2019 — Jan 2021 [monthly]

Completed PHASE2
Jul 2018 — Nov 2019 [monthly]

Completed PHASE2

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Chest Hospital

Data source: Shanghai Chest Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.